Filter By Category
Archives
Share on -
CAMIZESTRANT
Generic Name: CAMIZESTRANT
ABSTRACT -
Camizestrant (AZD9833) is a next-generation oral selective oestrogen receptor degrader (SERD) developed by AstraZeneca for hormone receptor-positive (HR+)/HER2-negative breast cancer. As a complete ER antagonist, it blocks ER transcriptional activity and promotes receptor degradation, overcoming limitations of partial SERD activity and resistance to aromatase inhibitors. Phase II trials (SERENA-2) demonstrated superiority over fulvestrant in ER+ advanced breast cancer.
DOSAGE -
75–150 mg orally once daily, studied in Phase II as monotherapy or in combination with CDK4/6 inhibitors; Phase III dose being confirmed.
SIDE EFFECTS -
- Nausea
- Fatigue
- Hot flushes
- Arthralgia
- QTc prolongation (dose-dependent)
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Skin rash
- Urticaria
- Drug hypersensitivity
- Angioedema (rare)
DRUG INTERACTIONS-
- CYP3A4 inhibitors increase camizestrant exposure
- Strong CYP3A4 inducers reduce efficacy — avoid
- QT prolongation additive with antiarrhythmics, fluoroquinolones
PREAUTONS–
- Baseline ECG and periodic QTc monitoring required
- Avoid in patients with congenital long QT syndrome
- Contraindicated in pregnancy — anti-oestrogenic teratogenicity
- Not studied in severe hepatic impairment
WARNINGS –
- QTc prolongation — dose-related, may require dose reduction
- Embryo-foetal toxicity — contraindicated in pregnancy
- Bone health monitoring recommended with long-term oestrogenic suppression
Share on -
. Developed by